Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
4.650
+0.100 (2.20%)
May 16, 2025, 2:08 PM - Market open
Precision BioSciences Revenue
Precision BioSciences had revenue of $29.00K in the quarter ending March 31, 2025, a decrease of -99.84%. This brings the company's revenue in the last twelve months to $51.14M, down -11.11% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm)
$51.14M
Revenue Growth
-11.11%
P/S Ratio
0.70
Revenue / Employee
$473,528
Employees
108
Market Cap
48.97M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DTIL News
- 1 day ago - Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 1 day ago - Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business Wire
- 8 days ago - Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - Business Wire
- 9 days ago - Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - Business Wire
- 15 days ago - Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business Wire
- 17 days ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - Business Wire
- 6 weeks ago - Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - Business Wire